In this week’s Innovation Partners BioBlog, we look at the challenges of designing new payment models for prescription drugs. The president seeks to align United States’ drug costs with those of its European counterparts; he also signed legislation this week to combat the opioid crisis. The CVS-Aetna merger continues apace, while other items of note ...

This week's Innovation Partners BioBlog offers updates from ESMO including biosimilars and studies on the treatment of men with breast cancer. Fourteen new insurers will offer Medicare Advantage plans in 2019, and Medicaid plan sponsors may provide incentives for preventative screenings. This and more in the Innovation Partners BioBlog, your weekly source of healthcare industry ...

This week’s Innovation Partner BioBlog looks at the ways in which various groups, governments and others are tackling the high cost of drugs. President Trump signed a bipartisan bill eliminating the gag clause for pharmacists, a move which could open the way for pharmacists to advise patients on lower-cost alternatives. Advertisements for drugs covered under ...

In this week's Innovation Partners BioBlog, some things stay the same while others are on the move. Aetna decided to keep its headquarters in Connecticut, reassuring the city of Hartford that it will stay put for at least a decade. Cancer detection is on the move with researchers at the University of Buffalo presenting a ...

Mergers, acquisitions, and changes abound this week in the world of healthcare. Aetna plans to sell its Medicare Part D business as part of its deal to go ahead with its CVS merger. UnitedHealth purchased Genoa and plans to fold it into its Optum RX business. Discussions of drug prices, value-based contracts and more are ...

Medicaid and Medicare are in the news this week, with Medicaid spending analysis anticipating a slightly lower than expected per enrollee cost. Alabama seeks to change Medicaid requirements and the Trump Administration unveils $1 billion in grants to combat the opioid crisis. This and more in this week’s Innovation Partners BioBlog. Medicaid spending hit $581B ...

The Department of Justice cleared yet another hurdle for Cigna to acquire PBM Express Scripts. FDA Commissioner Scott Gottlieb took aim at the CEO of a drug company, taking to social media to make add his comments to the ongoing dialogue on high drug costs. All across America, high prescription drug costs - and what ...

Can you trust comments online? Not always, according to the Washington Post, which revealed that among 1,400 comments on proposed cuts to a drug discount program many comments were duplicates or exact copies. A panel examined biosimilars and listened to the public's questions and concerns, and in Washington, Trump's health chief met with GOP lawmakers ...

Value-based drug pricing, looser restrictions on Part D drug formularies...it seems as if every group and organization is trying to help patients access and pay for their medications. In this week’s Innovation Partners BioBlog, we’ll take a look at oncology biosimilars, Medicaid value-based drug pricing, and much more. Do Oncology Biosimilars Have a Place in ...

This week’s Innovation Partners BioBlog takes a look at several aspects of the business of healthcare. First, the impressive news that the Cigna, Express Scripts deal to acquire PBM was approved by shareholders in both companies, a move that goes against expert predictions. Over 150 medical organizations and groups praise the Trump Administration’s efforts to ...